| Document |
Document Title |
|
WO/2014/078427A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/077292A1 |
In this method, an oligonucleotide is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R1, Y, Base, Z, Ar, R2, R3 and n are each as defined in Claim 1]. The novel nucleosi...
|
|
WO/2014/078295A1 |
The present invention provides compounds according to formula I and pharmaceutically acceptable salts thereof. For compounds of formula I, R1 and R2 are independently selected from the group consisting of H, -C(=O) (CH2)2-aryl, and C(=O)...
|
|
WO/2014/078463A1 |
The present invention relates to 2'-Alkynyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to co...
|
|
WO/2014/074883A1 |
Novel synthetic methods for preparation of LD101, a compound according to formula (A) are disclosed.
|
|
WO/2014/074725A1 |
In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods...
|
|
WO/2014/069645A1 |
Provided is an analysis technique for detecting 8-oxo-dG in DNA using a compound represented by formula (II). In formula (II): R3 is H, a protecting group of the 3'-hydroxyl group, oligodeoxynucleotide group 1 (ODN group 1) or -P(OR5)R6 ...
|
|
WO/2014/070771A1 |
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengu...
|
|
WO/2014/070948A1 |
Provided herein are methods of treating a disease or disorder associated with dysregulation of histone deacetylase, and more specifically sensitizing and treating chemoresistant cancer comprising administering a therapeutically effective...
|
|
WO/2014/066239A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/062596A1 |
The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relates to compositi...
|
|
WO/2014/059740A1 |
Disclosed are a compound as shown in formula (I) and pharmaceutically acceptable salts thereof. R1, R2, R3, R4, R5, W, and n are defined as in the description of the present application.
|
|
WO/2014/058801A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/059275A2 |
The present invention relates to novel strains of Streptomyces microflavus and methods of their use for controlling diseases or pests of a plant. The invention also relates to a fermentation broth obtained by cultivating a gougerotin pro...
|
|
WO/2014/053397A1 |
The present description refers to photocleavable compounds which can be used as a photocleavable linker in order to link two biomolecules, such as oligonucleotides and peptides. The present description further refers to a method for the ...
|
|
WO/2014/053897A1 |
A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step c...
|
|
WO/2014/048969A1 |
The present invention relates to a method for the isolation and/or identification of known or unknown sequences of nucleic acids (target sequences) optionally marked with reporter groups by base specific hybridation with, essentially, co...
|
|
WO/2014/052638A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2014/048998A1 |
The present invention relates to 5-fluorouracil derivatives represented by formula (i), pharmaceutical compositions comprising said derivative and their use in the treatment of cancer as well as a process for preparing the 5-fluorouracil...
|
|
WO/2014/047117A1 |
Processes for the production of nucleoside phosphoramidate compounds having the following Formula I are provided.
|
|
WO/2014/047199A1 |
The present invention provides a compound having the structure: (Formula (I)) wherein X is a therapeutic agent containing at least one amine nitogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon α; ...
|
|
WO/2014/046212A1 |
This oligonucleotide or pharmaceutically acceptable salt thereof contains a compound represented by formula I or II or a salt thereof, and at least one nucleoside structure represented by formula I' or II'. Thus provided is a nucleic aci...
|
|
WO/2014/043046A1 |
Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5'-methylthioadenosine deaminase (MTADA).
|
|
WO/2014/038561A1 |
Provided is a compound, a tautomer of said compound, a stereoisomer of said compound, or a salt of the compound, tautomer, or stereoisomer that is characterized by being represented by chemical formula (I). L is a single bond or a linker...
|
|
WO/2014/033617A1 |
The present invention provides a compound of formula A or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are defined herein, which is a 2'-branched nucleoside useful for the treatment or prevention of ...
|
|
WO/2014/028081A2 |
|
|
WO/2014/028739A1 |
Provided herein are methods for the solid phase synthesis of oligomeric compounds wherein at least one of the capping steps has been modified. More particularly, methods are provided wherein one or more of the capping steps is omitted or...
|
|
WO/2014/027658A1 |
A compound represented by general formula [1D] (in the formula, R1A, R1B, R2A, R2B, R3A and R3B each denote a hydrogen atom, an optionally substituted C1-6 alkyl group, and the like) is useful as an intermediate for producing a thionucle...
|
|
WO/2014/028079A1 |
Prostate cancer is treated by administration of N 6-benzyladenosine-5'- monophosphate or pharmaceutically acceptable salt thereof.
|
|
WO/2014/025272A1 |
The subject of the invention is a new method of the synthesis of polyphosphate analogues, such as nucleosides, oligonucleotides, carbohydrates, peptides and proteins, which are of biological importance and are used in organic chemistry, ...
|
|
WO/2014/022563A2 |
The present invention is directed towards the synthesis of high purity deuterated sugars, deuterated phosphoramidites, deuterated nucleobases, deuterated nucleosides, deuterated oligonucleotides, and deuterated RNA's of defined sequences...
|
|
WO/2014/022577A1 |
The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5'-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compou...
|
|
WO/2014/022839A1 |
The present invention provides nucleosides comprising a sterically hindered silyl protecting group on the exocyclic nitrogen atom of the nucleobase, oligonucleotides comprising the same, and methods for producing the same. In particular,...
|
|
WO/2014/017615A1 |
The purpose of the present invention is to provide: a monomer for the synthesis of RNA, which can be produced with high efficiency and consequently enables the remarkable reduction in the cost for the production of RNA; a method for prod...
|
|
WO/2014/016361A1 |
The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia Coli infections. Exemplary compounds are:
|
|
WO/2014/008344A1 |
The present invention relates to compounds and methods for treating retroviral infections, HIV, Hepatitis B, and/or HTLV viral infections. Some compounds of the invention are described by formula (I): or a pharmaceutically acceptable sal...
|
|
WO/2014/008236A1 |
The present invention is directed to a process for preparing diastereomerically enriched nucleoside phosphoramidates having the formula I:
|
|
WO/2014/007323A1 |
The present invention addresses the problem of providing a useful production intermediate for producing 1-[2'-deoxy-4'-thio-1'-β-D-ribofuranosyl]-5-fluorouracil and a production method using said intermediate. As a means for solving the...
|
|
WO/2014/003950A2 |
Nutritional supplements are described comprising selenium containing nucleosides. Methods of making the nutritional supplements and using the nutritional supplements are also described.
|
|
WO/2013/178571A1 |
An improved process for the preparation of (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidine derivatives of formula I, (I), wherein R1 is selected from C1-4-alkyl is described. The (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidine derivatives of formu...
|
|
WO/2013/176844A1 |
An oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligonucleotide derivative are disclosed. wherein R3 is a first oligonucleotide; R1 is selected from the group consisting of alkyl, cycloalky...
|
|
WO/2013/177188A1 |
Provided herein are compounds of formula (I) compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, whi...
|
|
WO/2013/174962A1 |
The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein,or a pharmaceutically acceptable salt or solvate thereof. The present invention also ...
|
|
WO/2013/177219A1 |
Provided herein are compounds comprising a D-amino acid, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives a...
|
|
WO/2013/177195A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2013/173759A2 |
The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprisin...
|
|
WO/2013/168627A1 |
The problem is to provide novel crystals of 5'-glucosyl adenosine the crystal structure of which has been elucidated, a 5'-glucosyl adenosine crystal-containing powder containing these crystals, the use of the same as a medical drug, and...
|
|
WO/2013/165266A1 |
The invention relates to a method of simultaneously protecting two functions which are the same or different, namely hydroxyl, amine, or thiol groups, particularly in sugars, polyalcohols, nucleosides, nucleotides, peptides, and nucleic ...
|
|
WO/2013/166121A1 |
Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; an...
|
|
WO/2013/166155A1 |
Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4)...
|
